Hans Schreiber to Mice, Inbred C57BL
This is a "connection" page, showing publications Hans Schreiber has written about Mice, Inbred C57BL.
Connection Strength
1.178
-
Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):7551-6.
Score: 0.088
-
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
Score: 0.085
-
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol. 2014 Feb 01; 192(3):1286-93.
Score: 0.074
-
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
Score: 0.070
-
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
Score: 0.065
-
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther. 2012 Mar; 20(3):652-60.
Score: 0.065
-
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
Score: 0.050
-
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008 Mar 01; 68(5):1563-71.
Score: 0.049
-
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22; 204(1):49-55.
Score: 0.046
-
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9.
Score: 0.038
-
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
Score: 0.037
-
Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004 Mar; 10(3):294-8.
Score: 0.037
-
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
Score: 0.035
-
Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5425-30.
Score: 0.035
-
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
Score: 0.034
-
Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s.
Score: 0.030
-
Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.
Score: 0.030
-
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med. 2000 Jun 05; 191(11):1945-56.
Score: 0.029
-
Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Exp Cell Res. 2020 08 15; 393(2):112014.
Score: 0.029
-
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
Score: 0.028
-
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
Score: 0.028
-
Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide. J Immunother. 1998 Jul; 21(4):277-82.
Score: 0.025
-
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997 Jul 21; 186(2):229-38.
Score: 0.024
-
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med. 1997 Feb 17; 185(4):695-705.
Score: 0.023
-
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug; 1(2):123-33.
Score: 0.018
-
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
Score: 0.018
-
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 2013 Feb; 62(2):359-69.
Score: 0.017
-
Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med. 1990 Apr 01; 171(4):1205-20.
Score: 0.014
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.012
-
A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity. Cancer Lett. 2005 Jun 16; 224(1):153-66.
Score: 0.010
-
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004 Feb; 5(2):141-9.
Score: 0.009
-
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med. 2003 Apr 21; 197(8):985-95.
Score: 0.009
-
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002 Oct 15; 62(20):5792-9.
Score: 0.009
-
Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J Immunol. 2001 Jun 15; 166(12):7151-7.
Score: 0.008